This website uses cookies to enhance the user experience.
S

SPERMVITAL AS993 936 294

Research
Limited company
Storhamargata 44 2317 HAMAR, Norge

SPERMVITAL AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Links

Organization

Chairman of the board
Years since formation
15 years
since May 12, 2009
Type
Limited company
VAT registered
Yes
Number of employees
11

Ownership

Number of shares and share classes
13,180
1 share class
Total number of shareholders
2
companies
Belongs to group of

Financials

Total operating income 2023
20,901,910
NOK
Annual total result 2023
-2,545,545
NOK
Total equity 2023
7,395,193
NOK
Last update: Sep 2, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Chairman-
Board Member-
Board Member-
Board Member-
Board Member-
Alternate Member-

Others

NameRoleShares
P
PRICEWATERHOUSECOOPERS AS
Auditor-
Last update: Oct 10, 2023

Ownership

Company shareholders

NameShare classNumber of sharesShare
G
GENO SA
Ordinary shares
11,578
87.85 %
S
SPERMVITAL INVEST AS
Ordinary shares
1,602
12.15 %
Last update: May 24, 2024

Group structure

  • Total operating income 2023: NOK 428,816,000
    Operating profit 2023: NOK 6,730,000
    Employees: 190

Financials

in NOK

Summary

Year202320222021
Total operating income
20,901,910
22,308,755
19,115,641
Annual Total Result
-2,545,545
673,714
-1,604,288
Total assets
28,064,987
33,268,358
31,765,366
Total liabilities
20,669,794
23,327,620
22,498,342
Total equity
7,395,193
9,940,738
9,267,024

P&L

Year202320222021
Total operating income
20,901,910
22,308,755
19,115,641
Total operating costs
23,227,072
21,409,816
20,482,297
Operating result
-2,325,162
898,939
-1,366,656
Financial income/costs
-220,383
-225,225
-237,632
Profit before tax
-2,545,545
673,714
-1,604,288
Total tax & extraordinary income/cost
0
0
0
Annual Total Result
-2,545,545
673,714
-1,604,288

Balance overview

Year202320222021
Total fixed assets
19,145,237
20,074,148
19,748,371
Total current assets
8,919,750
13,194,210
12,016,995
Total assets
28,064,987
33,268,358
31,765,366
Short term debt
5,597,727
6,385,097
5,253,452
Long term debt
15,072,067
16,942,523
17,244,890
Total liabilities
20,669,794
23,327,620
22,498,342
Contributed capital
17,199,820
17,199,820
17,199,820
Retained earnings
-9,804,627
-7,259,082
-7,932,796
Total equity
7,395,193
9,940,738
9,267,024
Total equity and liabilities
28,064,987
33,268,358
31,765,366

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology